Joe Byrd (Cherokee Nation Principal Chief)

Neuros Medical Announces Completion of Enrollment in the QUEST Pivotal Clinical Study for Chronic Post-Amputation Pain

Wednesday, September 15, 2021 - 4:15pm

QUEST is designed to assess the safety & effectiveness of the Company's AltiusHigh-Frequency Nerve Block system to treat intractable post-amputation pain.

Key Points: 
  • QUEST is designed to assess the safety & effectiveness of the Company's AltiusHigh-Frequency Nerve Block system to treat intractable post-amputation pain.
  • Post-amputation pain is a significant unmet medical need, as existing treatment options are limited, and consist primarily of opioids and gabapentinoids.
  • Neuros Medical, a neuromodulation company, has developed the Altius system for the treatment of chronic post-amputation pain (phantom limb pain and residual limb pain).
  • Post-amputation pain includes both phantom limb and residual limb (or "stump") pain, and impacts nearly one million Americans.

Michigan's High Street Insurance Partners Expands Executive Leadership

Tuesday, September 7, 2021 - 2:29pm

TRAVERSE CITY, Mich., Sept. 7, 2021 /PRNewswire/ --High Street Insurance Partners ("HSIP") announced today the appointments of Angela Williams to Chief Brand Officer and Emma Riza to Chief Development Officer.

Key Points: 
  • TRAVERSE CITY, Mich., Sept. 7, 2021 /PRNewswire/ --High Street Insurance Partners ("HSIP") announced today the appointments of Angela Williams to Chief Brand Officer and Emma Riza to Chief Development Officer.
  • All three leaders will join the Executive Leadership Team and will report toScottGoodreau, Managing Partner & Chief Operating Officer effective today.
  • "Both Angela and Emma's ability to help build the strategic direction of High Street make them the ideal fit," saidScottWick, HSIP's Chief Executive Officer.
  • High Street Insurance Partners is a full-service independent insurance brokerage firm.

Five-year Results Of The GORE® EXCLUDER® Iliac Branch Endoprosthesis Pivotal U.S. Multicenter Study Confirm Safety, Efficacy and Durability

Thursday, August 19, 2021 - 5:01pm

Results of the study confirmed the safety, efficacy and durability of the IBE for treatment of aortoiliac and iliac artery aneurysms.

Key Points: 
  • Results of the study confirmed the safety, efficacy and durability of the IBE for treatment of aortoiliac and iliac artery aneurysms.
  • Five-year primary patency of the internal iliac artery and external iliac artery IBE limbs was 95.1% and 100%, respectively.
  • Used in conjunction with the GORE EXCLUDER AAA Endoprosthesis, the IBE isolates the common iliac artery from systemic blood flow and preserves blood flow in the external iliac and internal iliac arteries.
  • For more information on the GORE EXCLUDER Iliac Branch Endoprosthesis and the GORE EXCLUDER Device family, visit goremedical.com .